Personalized Medicine: Worth Its Cost?

Percivil Melendez Carrera

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Already stretched health care systems face a panoply of challenges, including a high and increasing number of patients with chronic conditions, expensive and rising costs of treatment, and stagnant economies. Not surprisingly, even as specialty pharmaceuticals—or, more broadly, personalized medicine—are touted as the future of medical care because they make more treatments more effective, there are reservations about the value that they offer society as a whole, compared to certain population groups. The findings of Bradford Hirsch and coauthors (Oct 2014) certainly help justify the efficiency and equity concerns of payers and health authorities about the impact of specialty pharmaceuticals. To be sure, we know little about the intended and unintended health, economic, and social impacts of personalized medicine. Advocates claim that personalized medicine provides value for money, as illustrated by the French case of universal molecular testing and targeted treatment of lung cancer patients with epidermal growth factor receptor mutation.1 The sustainability of these benefits, unfortunately, is far from established. Personalized medicine is still both hype and hope. Arguably, the challenge is to produce a preponderance of clear and convincing evidence that specialty pharmaceuticals and personalized medicine are worth their cost.2
Original languageEnglish
Pages (from-to)188-
JournalHealth affairs
Volume34
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Precision Medicine
Costs and Cost Analysis
Health
Social Change
Population Groups
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Health Care Costs
Lung Neoplasms
Economics
Delivery of Health Care
Therapeutics

Keywords

  • IR-94487
  • METIS-309390

Cite this

Carrera, Percivil Melendez. / Personalized Medicine: Worth Its Cost?. In: Health affairs. 2015 ; Vol. 34, No. 1. pp. 188-.
@article{b1c44df45c1541269ae7113b589ab969,
title = "Personalized Medicine: Worth Its Cost?",
abstract = "Already stretched health care systems face a panoply of challenges, including a high and increasing number of patients with chronic conditions, expensive and rising costs of treatment, and stagnant economies. Not surprisingly, even as specialty pharmaceuticals—or, more broadly, personalized medicine—are touted as the future of medical care because they make more treatments more effective, there are reservations about the value that they offer society as a whole, compared to certain population groups. The findings of Bradford Hirsch and coauthors (Oct 2014) certainly help justify the efficiency and equity concerns of payers and health authorities about the impact of specialty pharmaceuticals. To be sure, we know little about the intended and unintended health, economic, and social impacts of personalized medicine. Advocates claim that personalized medicine provides value for money, as illustrated by the French case of universal molecular testing and targeted treatment of lung cancer patients with epidermal growth factor receptor mutation.1 The sustainability of these benefits, unfortunately, is far from established. Personalized medicine is still both hype and hope. Arguably, the challenge is to produce a preponderance of clear and convincing evidence that specialty pharmaceuticals and personalized medicine are worth their cost.2",
keywords = "IR-94487, METIS-309390",
author = "Carrera, {Percivil Melendez}",
year = "2015",
doi = "10.1377/hlthaff.2014.1376",
language = "English",
volume = "34",
pages = "188--",
journal = "Health affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "1",

}

Personalized Medicine: Worth Its Cost? / Carrera, Percivil Melendez.

In: Health affairs, Vol. 34, No. 1, 2015, p. 188-.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Personalized Medicine: Worth Its Cost?

AU - Carrera, Percivil Melendez

PY - 2015

Y1 - 2015

N2 - Already stretched health care systems face a panoply of challenges, including a high and increasing number of patients with chronic conditions, expensive and rising costs of treatment, and stagnant economies. Not surprisingly, even as specialty pharmaceuticals—or, more broadly, personalized medicine—are touted as the future of medical care because they make more treatments more effective, there are reservations about the value that they offer society as a whole, compared to certain population groups. The findings of Bradford Hirsch and coauthors (Oct 2014) certainly help justify the efficiency and equity concerns of payers and health authorities about the impact of specialty pharmaceuticals. To be sure, we know little about the intended and unintended health, economic, and social impacts of personalized medicine. Advocates claim that personalized medicine provides value for money, as illustrated by the French case of universal molecular testing and targeted treatment of lung cancer patients with epidermal growth factor receptor mutation.1 The sustainability of these benefits, unfortunately, is far from established. Personalized medicine is still both hype and hope. Arguably, the challenge is to produce a preponderance of clear and convincing evidence that specialty pharmaceuticals and personalized medicine are worth their cost.2

AB - Already stretched health care systems face a panoply of challenges, including a high and increasing number of patients with chronic conditions, expensive and rising costs of treatment, and stagnant economies. Not surprisingly, even as specialty pharmaceuticals—or, more broadly, personalized medicine—are touted as the future of medical care because they make more treatments more effective, there are reservations about the value that they offer society as a whole, compared to certain population groups. The findings of Bradford Hirsch and coauthors (Oct 2014) certainly help justify the efficiency and equity concerns of payers and health authorities about the impact of specialty pharmaceuticals. To be sure, we know little about the intended and unintended health, economic, and social impacts of personalized medicine. Advocates claim that personalized medicine provides value for money, as illustrated by the French case of universal molecular testing and targeted treatment of lung cancer patients with epidermal growth factor receptor mutation.1 The sustainability of these benefits, unfortunately, is far from established. Personalized medicine is still both hype and hope. Arguably, the challenge is to produce a preponderance of clear and convincing evidence that specialty pharmaceuticals and personalized medicine are worth their cost.2

KW - IR-94487

KW - METIS-309390

U2 - 10.1377/hlthaff.2014.1376

DO - 10.1377/hlthaff.2014.1376

M3 - Article

VL - 34

SP - 188-

JO - Health affairs

JF - Health affairs

SN - 0278-2715

IS - 1

ER -